Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Astex Therapeutics
Biotech
Otsuka's guadecitabine flunks 2 more late-phase cancer trials
Guadecitabine has now failed three late-phase trials, leaving Otsuka to weigh up the next steps for a drug it acquired in an $886 million takeover.
Nick Paul Taylor
Oct 15, 2020 8:18am
Merck puts $2.5B biobucks down for KRAS deal
Jan 6, 2020 4:19am
Otsuka’s guadecitabine fails phase 3 AML trial
Jul 31, 2018 8:27am
Woodford invests in Big Pharma-backed dementia fund
Jun 19, 2017 4:59am
EuroBiotech Report—Cell Medica, Astex, Galapagos and more
Mar 16, 2017 9:43am
Astex bags milestone after Novartis cancer drug approved
Mar 14, 2017 9:28am
